Stopping renin-angiotensin-aldosterone inhibitors after hyperkalemia may offset their potential clinical benefits, according to investigators. Continuation of angiotensin-converting enzyme (ACE) ...

Please provide your email address to receive an email when new articles are posted on . Fewer patients with hyperkalemia were prescribed renin-angiotensin-aldosterone system inhibitors for HF.

March 24, 2011 (Edmonton and Calgary, Alberta) — In clinical practice and as has been seen in clinical trials, combining an angiotensin-converting enzyme (ACE) inhibitor with an angiotensin-receptor ...

Please provide your email address to receive an email when new articles are posted on . Half of participants experienced a clinically meaningful decrease in albuminuria after taking BI 690517. Of ...

"Patients who experience hyperkalemia while on RAAS inhibitor therapy may benefit from intensification of other evidence-based preventative measures against adverse cardiorenal outcomes, such as lipid ...

In patients with type 2 diabetes (T2D), the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and sustained use of guideline-recommended renin ...

Medically reviewed by Paria Sanaty Zadeh, PharmD Key Takeaways Serious side effects are more likely to occur when taking high doses, particularly in people with certain health conditions like kidney ...